More than 100,000 patients each year need renal replacement therapy - dialysis and renal transplant. Most of these patients develop anaemia and will need drugs to maintain their haemoglobin and reduce the need for blood transfusions. While Cipla incubates its own pipeline, we also look forward to partner with companies in India and around the world to bring wider access of biosimilar products to patients in need," Gogtay added. Last year, Cipla had launched biosimilar of Etanercept under the brand name 'Etacept' used for treatment of rheumatic disorders in India. Under the agreement, Etacept is manufactured by a China-based Shanghai CP Guojian Pharmaceutical Co Ltd, and marketed by Cipla in India.